1 *Review*

Ricin: an ancient story for a timeless plant toxin

3 **Letizia Polito#,*, Massimo Bortolotti#, Maria Giulia Battelli#, Giulia Calafato and Andrea**
4 **Bolognesi***

5 Department of Experimental, Diagnostic and Specialty Medicine—DIMES, General Pathology Section, Alma
6   Mater Studiorum—University of Bologna, Via S. Giacomo 14, 40126 Bologna, Italy;
7   massimo.bortolotti2@unibo.it (M.B.); mariagiulia.battelli@unibo.it (M.G.B.); giulia.calafato2@unibo.it (G.C.)
8 # These authors equally contributed to this work
9 * Correspondence: letizia.polito@unibo.it, andrea.bolognesi@unibo.it (L.P., A.B.); Tel.: +39-051-209-4700

10

11 **Abstract:** The castor plant (*Ricinus communis* L.) has been known since time immemorial in
12 traditional medicine in the pharmacopeia of Mediterranean and eastern ancient cultures. Moreover,
13 it is still used in folk medicine worldwide. Castor bean has been mainly recommended as anti-
14 inflammatory, anthelmintic, anti-bacterial, laxative, abortifacient, for wounds, ulcers, and many
15 other indications. Many cases of human intoxication occurred accidentally or voluntarily with the
16 ingestion of castor seeds or derivatives. Ricinus toxicity depends on several molecules, among them
17 the most important is ricin, a protein belonging to the family of ribosome-inactivating proteins. Ricin
18 is the most studied of this category of proteins and it is also known to the general public, having
19 been used for biocrimes in several cases. Here, the main steps of ricin research are reported with
20 particular regards to its enzymatic activity, structure and cytotoxicity. Moreover, we discuss ricin
21 toxicity for animals and humans, as well as the relation amongst bioterrorism and ricin and its
22 impact on environmental toxicity. Ricin has also been of great utility to develop a number of
23 immunotoxins specific for the elimination of unwanted cells, mainly cancer cells; some of these
24 immunotoxins gave promising results also in clinical trials.

25 **Keywords:** castor bean; cancer therapy; immunotoxins; plant toxins; ribosome-inactivating
26 proteins; ricin; rRNA N-glycosylase activity; traditional medicine; folk medicine; bioterrorism

27 **Key Contribution:** This manuscript points out the most known plant toxin: ricin. Starting from the
28 use of *Ricinus* plant in traditional and folk medicine; we highlight the milestones of research on ricin;
29 with particular regards to its enzymatic activity; structure; cytotoxicity; toxicity for animals and
30 humans and the double face of its employ, for biocrimes and medicine.

31

1. Castor bean in traditional and folk medicine

33   The toxin ricin derives from *Ricinus communis* L. (Euphorbiaceae family), also known as castor
34 bean or *palma Christi*. The genus Ricinus has only one known species: the castor oil plant. The plant
35 possibly originates from Africa and Asia and now is widespread throughout temperate, subtropical
36 and tropical areas, growing as an invasive plant or being cultivated for different purposes also in
37 Westland.
38   The castor plant has been known since time immemorial and its use in prehistoric era is
39 evidenced by archaeological findings such as that of the Border Cave in South Africa. Traces of wax
40 containing ricinoleic and ricinelaidic acids were found on a thin wooden stick, which was suggested
41 to be a poison applicator, dating back to about 24,000 years ago [1]. The castor seeds and other parts
42 of the castor plant were certainly utilized in ancient Egypt for pharmacological purposes. In the Ebers
43 Papyrus., an Egyptian medical treatise dating back to before 1500 BCE, an entire chapter is dedicated
44 to castor bean that is indicated as abortifacient, laxative, for treatment of abscessual illness, for

45 baldness and so on [2]. In the Hearst Papyrus, written approximately in the same period, various
46 castor plant parts are included as ingredients in some prescriptions for internal use with the aim of
47 expelling fluid accumulation or promoting diuresis, as well as for external use as poultices for
48 bandaging [3]. Ancient Egyptians knew the toxicity of castor bean and only small amounts of the
49 seeds pulp were included in drug preparations for oral ingestion, which were prescribed mostly with
50 abortifacient or laxative purposes. In addition, a castor seed-containing concoction was
51 recommended to cure the urinary disease of a possibly diabetic child [4]. Around 400-year BCE, the
52 father of western medicine Hippocrates prescribed castor bean oil for laxative and detoxifying action
53 [5]. The Greek herbalist and physician Pedanius Dioscorides (40–90 CE) in *De Materia Medica* wrote
54 that castor seeds could be used as expectorant, diuretic, emetic, laxative, anti-inflammatory, to cure
55 erysipelas, burns, varicose veins, etc [6]. In the same period, Pliny the Elder (23-79 CE) wrote *Naturalis*
56 *historia*, comprising the whole area of antique knowledge. In this encyclopedic work there is a place
57 also for castor bean [7].

58   Castor bean was used also in the pharmacopeia of eastern ancient cultures. In Chinese traditional
59 medicine, castor seeds were recommended for their anthelmintic activity; seed poultice and leaf juice
60 were prescribed for external use to treat ulcers and chronic wounds, whereas the latex was instilled
61 in the ear to recover patient from rhinitis (reviewed in [8]). Castor plant is called *erandah* in Sanskrit,
62 because of its reputation of being a remedy for all kind of diseases. In Ayurveda, castor plant is used
63 for rheumatic affections, as well as for gastropathy, constipation, inflammations, fever, ascites,
64 bronchitis, cough, skin diseases, colic and lumbago. In Yunani medicine, castor root is used as
65 purgative and for skin diseases, the leaves are used to increase breastmilk production and for burns,
66 the seeds and the oil from them are purgative, useful in liver troubles, pains, lumbago, boils, piles,
67 ringworm, inflammations, ascites, asthma, rheumatism, dropsy and amenorrhea (reviewed in [9]).
68 Ground castor seeds or leaf paste were applied in veterinary medicine to heal sprains, swellings and
69 wounds [10].

70   Castor bean is used in folk medicine widespread throughout the world and has been reported:
71 (i) as a galactogogue on the Mediterranean coasts of Europe, where fresh leaves or leaf juice are
72 applied on the puerperal breast to promote lactation; (ii) as a remedy for various articular, cutaneous
73 or ocular diseases in Africa, where crushed seeds or oil, sometimes in combination with other plants,
74 are spread or rubbed on the sickling part of the body, or a root decoction is drunk to induce uterine
75 contraction as an abortive; (iii) as a medicament to cure erysipelas, flu, inflammation of the womb
76 and stomach aches in the Caribbean, where a leaf poultice is recommended; (iv) as an anthelmintic
77 or a purgative in Brazil where the seed oil is orally assumed or locally applied with the purpose of
78 contrasting the hair loss or of healing wounds or burns (reviewed in [11]).
79   The laxative and abortifacient activities of castor seeds were attributed to the activation of
80 intestinal and uterine smooth-muscle cells via prostaglandin EP3 receptors induced by ricinoleic acid
81 [12]. Castor oil-induced diarrhea can be antagonized by hexane extract of *Citrus limon* peel that
82 activates antisecretory and antimotility mechanisms through the β adrenergic system [13]. The
83 purgative and anthelmintic actions of the oral ingestion of castor seeds, at least in part, could also be
84 ascribed to the irritative effect caused to intestine by ricin, as reported in toxicological studies
85 (reviewed in [14]). In addition, the antiflogistic action of castor bean could be related to the high
86 toxicity of ricin to macrophagic cells, which are responsible of producing inflammatory cytokines
87 (reviewed in [15]). This effect, together with the anti-pathogen activity of ricin, could promote healing
88 of the lesions, thus justifying its use in the treatment of various skin affections.

89 **2. The ricin story**

90   In the past centuries, castor oil had many uses; it was obtained by crushing the seeds and the
91 process produced a significant amount of residual press cake that was known to contain a highly
92 toxic component. Castor seed toxicity began to be investigated at the end of nineteenth century at

93 Schmiedeberg's laboratory in Strasbourg. The toxic component of Ricinus could be extracted with
94 water and precipitated with alcohol, but it lost its toxic activity through heating, treatment with
95 strong acid or repeated precipitation with alcohol. In 1887, Dixson supposed that the toxicity of
96 Ricinus was due to a protein [16]. However, there were still many doubts whether the seed toxicity
97 was due to a protein or a glycoside (reviewed in [17]). The problem was solved at the Medical Faculty
98 of Dorpat (now Tartu) where an extremely toxic protein was partially purified from castor seed or
99 press cake and named ricin in the doctoral thesis written by Hermann Stillmark under the
100 supervision of Prof. Rudolf Kobert [18]. Stillmark noticed the agglutinating activity of ricin on red
101 blood cells that was mistakenly believed to be the cause of ricin toxicity until the agglutinin was
102 separated from the toxin [19].

103   Paul Ehrlich began his experiments in immunology by feeding mice with small amount of ricin
104 or abrin, another similar plant toxin, until they were accustomed and became resistant to the toxin
105 used, still remaining sensitive to the other toxin. The immunization was strictly specific, started after
106 a few days and persisted at least for several months [20,21]. He was successful in the production of
107 antisera against abrin and ricin and in the determination of antibody titer in serum and milk. Ehrlich
108 drew animal experiments that clarified the transmission of passive immunity from mother to
109 offspring through the transplacental transfer of antibodies and the breastfeeding. He investigated the
110 dynamics of the antibody response and was the first to envisage the presence of binding sites on the
111 cell surface (reviewed in [22]). These studies together with those on the immunity to bacterial toxins
112 led him to formulate his side-chain theory of antibody formation and to win, in 1908, the Nobel Prize
113 [23].

114   Interest in ricin was rekindled when the anticancer activity of this toxin on Ehrlich ascites cells
115 in a mouse model was published [24]. A strong inhibition of protein synthesis by ricin was observed
116 in cultures of both Ehrlich ascites tumour cells and Yoshida ascites hepatoma cells. The inhibition of
117 protein synthesis by ricin requires more time in rat liver than in neoplastic cells [36]. The prospect of
118 a possible use in cancer therapy induced to investigate which part of the proteosynthetic machinery
119 was damaged and how the toxin managed to enter the cell to reach its target. In this paper, we
120 highlight the milestones of research on ricin, with particular regards to its enzymatic activity,
121 structure, cytotoxicity, toxicity for animals and humans and employ as immunotoxins, used in
122 experimental models and in clinical trials. The main milestones are shown in Figure 1.

123 *2.1. Ricin structure*

124   The first information about the bi-chain nature of ricin structure dates to the early 70s, when it
125 was shown that ricin was composed by two chains, A (active) and B (binding), linked together
126 through a disulphide bond [26,27]. In the same period, the complete primary sequence of the ricin A
127 and B chains was determined [28,29]. Ricin holotoxin structure was solved for the first time at 2.8 Å
128 resolution (Figure 1) [30]. This pioneering work demonstrated that ricin A chain was a globular
129 protein folded into three domains all contributing to the active site, while the B chain lectin folded
130 into two domains, each binding lactose in a shallow cleft. The interface between the A and B chains
131 showed some hydrophobic contacts in which proline and phenylalanine side chains played a
132 prominent role. Four years later, the same researchers refined ricin structure at 2.5 Å (Figure 2a),
133 allowing a more detailed molecular description of the holotoxin and of the separated A and B chains
134 [31-33].

135

136   **Figure 1.** The main milestones of ricin research.

137   Ricin A chain was described as a globular protein consisting of 267 aminoacids and organized
138   in 8 α-helices and 8 β-strand structures. Ricin B chain consists of 262 aminoacids and two homologues
139   domains, each containing a lactose binding site and several areas of aminoacid homology, possibly
140   derived from a gene duplication. In 1995, after purification of a complex of ricin A chain cross-linked
141   to the ribosome, it was found the binding of ricin A chain with the ribosomal proteins L9 and L10e
142   [34,35].
143   The knowledge of tridimensional structure of ricin yielded more information on its active site.
144   Studies based on the formation of complexes between the A chain, both native and recombinant, and
145   adenine-containing nucleotides allowed the identification of key residues in enzymatic activity. In
146   particular, Tyr80, Tyr123, Glu177, Arg180 and Trp211 were found to form the binding site for adenine
147   (Figure 2b) [30,36]. In the 90s, the molecular mechanism of de-adenilation was hypothesized: adenine
148   is sandwiched between Tyr80 and Tyr123 in a π stacking interaction; the N3 of adenine is protonated
149   by Arg180, promoting the C1'-N9 bond breaking thus forming an oxycarbenium moiety on the ribose
150   (Figure 2c) [36,37]. This transition state is stabilized by Glu177; a water molecule lies on the opposite
151   side of the sugar ring from adenosine, which will be polarized by Arg180 to a hydroxide character
152   that rapidly attacks the sugar carbon completing the reaction.

Figure 2. (a) Ribbon model of the crystal structure of ricin at 2.5 Å (accession number Protein Data Bank 2AAI). The A chain domains are colored in green, blue and light blue; the B chain domains are colored in yellow and orange. (b) Catalytic site of ricin. The key residues are indicated and colored in blue, whereas adenine substrate is depicted in red. (c) Proposed mechanism of depurination reaction catalyzed by ricin. The hydrolysis proceeds through a dissociative mechanism forming an oxocarbenium transition state. Arg180 protonates the leaving group and the N-glycosidic bond is broken. Glu177 deprotonates the hydrolytic water (highlighted in red dotted rectangle) that attacks at carbon to complete the depurination reaction. Figure 2a and 2b were produced by PyMOL (version 2.3.1); Figure 2c was produced by ACD/ChemSketch (version 2015.2.5).

2.2. Ricin enzymatic activity

The introduction of a cell-free system utilizing a lysate from rabbit reticulocytes [38] helped to clarify that ricin inhibited the peptide chain elongation (Figure 1) [27]. The two polypeptides showed different properties: the A chain possessed the toxic activity, while the B chain was a galactose-specific lectin binding the cell surface [26]. Treating the toxin with reducing agents, it resulted more active in inhibiting cell-free protein synthesis [39]. Firstly, the target of the toxic action was identified as the ribosome (Figure 1), then as the 60 S subunit of eukaryotic ribosome [40], which became unreactive toward elongation factors [41]. The toxin was found to interfere with the interaction of elongation factors with the ribosomes and their elongation-factor-dependent GTPase activity [41,42]. The A-chain molecule resulted very active on its substrate and it was calculated that one molecule can inactivate 2000 ribosomes/min, with a K_m of 0.1-0.2 mM [43].

In addition to ricin, several other plant proteins have been identified to possess a similar protein synthesis inhibiting action. Most of them had a single polypeptide chain similar to the A chain of ricin. They were called Ribosome-Inactivating Proteins (RIPs) (reviewed in [44,45]).

The already supposed enzymatic nature of ricin A chain was finally demonstrated in 1987 by Endo and Co-workers, which discovered that ricin A-chain cleaved the N-glycosidic bond of an adenine residue, A4324 in rat 28 S RNA, from the ribose of a highly conserved ribosomal RNA single-stranded loop involved in the binding of elongation factors (Figure 1). The toxin did not directly break the RNA chain, but the depurinated RNA was susceptible to hydrolysis [46,47]. Consequently, ricin activity was identified as an rRNA N-glycosidase [EC 3.2.2.22].

183   After, it was demonstrated that the enzymatic activity of RIPs was broader than previously
184   described. All tested RIPs were able to deadenylate DNA, in addition to rRNA, and some of them
185   were also able to deadenylate different other polynucleotide substrates, releasing adenine from the
186   sugar phosphate backbone of polynucleotide substrates (Figure 1) [48,49]. For this reason, the name
187   of adenine polynucleotide glycosylase was proposed for RIPs. Thus, the ability of acting on various
188   substrates and extensively depurinating some of them suggested that the protein synthesis inhibition
189   could be only one of the ways of RIP-mediated cell killing. Ricin resulted able to deadenylate rRNA,
190   DNA (chromatin and naked) and also poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase, an
191   enzyme involved in DNA repair [48,50]. Furthermore, it was observed that many RIPs were able to
192   cleave more than one adenine; although ricin was able to detach few adenines from the DNA (tens),
193   less than some single-chain RIPs (thousands). The hypothesis that ricin could act directly on DNA in
194   cellular models was strengthened by the evidence that damage to nuclear DNA, consistent with the
195   enzymatic activity (adenine release) on DNA in cell-free systems, was concomitant with protein
196   synthesis inhibition and preceded apoptosis [51].

197   *2.3. Ricin cellular uptake, routing and toxicity*

198   Starting from the mid-70s, several research groups focused on ricin binding and internalization
199   studies, demonstrating that the interaction of ricin with the cell started from the binding of the B
200   chain to galactosyl residues on cell surface, allowing the access to endosomal compartment [52]. Ricin
201   binds to both glycolipids and glycoproteins with terminal galactose. Since ricin binds to a variety of
202   different molecules, it seems to be internalized by different endocytic pathways as well as to use
203   different pathways to reach the Golgi apparatus and to intoxicate the cell. In HeLa cells, about 10^7
204   binding sites were found for ricin, but only small amount of the bound toxin reached the Golgi
205   network and participated to the cell intoxication [52].

206   Firstly, it was reported that ricin entered into cytoplasm through clathrin-dependent endocytosis
207   [53]. Afterwards, it became clear that also clathrin-independent mechanisms were involved [54].
208   After cell uptake, ricin is delivered to early endosomes, from where most of protein molecules are
209   recycled back to the cell surface or delivered, via late endosomes, to lysosomes for proteolytical
210   degradation. A small amount of not degraded ricin is addressed within the trans-Golgi network [55].
211   The involvement of Golgi complex in ricin routing was confirmed using different Golgi-disrupting
212   agents, such as brefeldin A, monensin, etc. In fact, the pretreatment with these agents inhibited the
213   cytotoxic effects of ricin [56]. It was demonstrated that ricin was cycled from Golgi to endoplasmic
214   reticulum via coatomer protein 1 (COP-1)-coated vesicles [57], although it was later proved that also
215   the COP-1-independent pathway could be involved [58].

216   The complete elucidation of intracellular ricin traffic occurred when it was demonstrated that,
217   after reaching the endoplasmic reticulum, the two ricin chains were separated, and the A chain was
218   retro-translocated through the quality control pathway delivering misfolded proteins to cytosol
219   (Figure 1) [59]. Recently it has been demonstrated that cholesterol rafts are required for Golgi
220   transport of ricin; instead, glycosphingolipids seem to be not required (reviewed in [60]).

221   The portion of A chain that quickly refolded, thus avoiding ubiquitination and proteosomal
222   degradation, was able to reach its intracellular target (reviewed in [61]). It was estimated that one
223   molecule of active ricin that arrives to its substrate is enough to kill one cell [62].

224   The discovery that ricin and some related toxins may be retrogradely transported along neuronal
225   processes (Figure 1) [63] opened a new field of research in neurobiology and this property has been
226   exploited for the selective destruction of neuron bodies.

227   Different cell types showed variable levels of sensitivity to ricin (reviewed in [14]), possibly
228   because of the mannose receptor expression on cell surface and the endocytosis efficacy. Ricin results
229   one of the most toxic plant toxins on cell lines with $IC_{50}s$ (concentration inhibiting protein synthesis
230   by 50%) ranging from less than 0.1 to 1 pM [26,64-66]. However, it must be taken into account that it

231 is very difficult to make a direct comparison of the data available in literature about ricin cytotoxicity,
232 because of the differences in the experimental approaches and technical conditions.

233   The polynucleotide depurinating activity of RIPs suggests the possibility of a wider toxic action
234 on many biological substrates, not excluding the induction of oxidative stress, all together justifying
235 the existence of more than one death mechanism induced by ricin and other RIPs, such as apoptosis
236 and necroptosis (Figure 1) [64,67].

3. Ricin toxicity in humans and animals

238   On one hand, ricin has been studied for bio-medical applications, exploiting the ability of the A-
239 chain to kill target cells once linked to a monoclonal antibody, as below described in the
240 immunotoxins chapter. On the other hand, ricin has attracted nefarious interests, with a history of
241 military, criminal and terroristic uses [68].

242   The acute toxicity of ricin is highly variable depending on the animal species and the strain. The
243 pathological effects and subsequent clinical signs of ricin intoxication depend also on the route of
244 exposure, as this dictates the subsequent tissue distribution of the toxin. Following intravenous or
245 intramuscular administration, lesions eventually develop in the spleen, liver and kidney whilst the
246 lung remains unaffected. After oral ingestion, the gastrointestinal tract is severely affected.
247 Inhalational exposure produces effects that are mainly confined to the respiratory tract [69].

248   Main data on animal toxicity derived from laboratory experiments in rodents, principally rat
249 and mouse. Oral administration of ricin was reported to give Lethal Dose for 50% of animals (LD_{50}s)
250 of 20-30 mg/kg in rat and 15–35 mg/kg in mouse [70-72]. For intravenous, inhalation and
251 intraperitoneal routes, toxicity is approximately 1000-fold higher than for oral route, with LD_{50} values
252 in mouse of 2-10 µg/kg, 3-5 µg/kg and 22 µg/kg, respectively [70,73]. The lower toxicity of ricin after
253 oral exposure is due to the protein destruction in the lumen of the intestinal tract [74,75]. Ricin acts
254 in a time- and concentration-dependent manner. Notably, there is a time delay of about 10 h before
255 death occurs even when very high doses are applied [76].

256   *Oral toxicity.* In human, most intoxications occurred accidentally or voluntarily with the
257 ingestion of castor seeds; only few cases of intentional absorption of castor bean extracts have been
258 documented in suicide attempts [76]. Whole-ingested beans can pass intact through the
259 gastrointestinal tract, whereas chewing facilitates ricin release. Also, it has been reported that the seed
260 can act as "timed-release" capsule for the toxin, allowing its release in the lower bowel, where it
261 causes more damage [72]. After ingestion, vomiting, diarrhea and abdominal pain are common
262 symptoms. Massive gastrointestinal fluid and electrolyte loss are described, often complicated by
263 hematemesis or melaena. Finally, hypovolemic shock and multiorgan failure occur, which
264 particularly involves spleen, liver and kidney [77,78].

265   Despite the high number of intoxicated subjects with castor beans, it is quite difficult to calculate
266 LD values for ricin in humans. In fact, the effective ingested ricin dose can only be supposed, because
267 of ricin content variations depending on size, weight and moisture of seeds, as well as on cultivar,
268 region, season and plant growth stage. Moreover, in intoxicated subjects, it must be taken into
269 account the degree of mastication, stomach content, age and comorbidities, parameters that are
270 obviously more heterogeneous compared to experimental poisoning of animals. Considering all
271 these parameters, the fatal oral dose of ricin in humans has been estimated to range from 1 to 20
272 mg/kg (approx. 5-10 beans) [70,79].

273   *Inhalation toxicity*. No data are available for human ricin uptake by inhalation. In non-human
274 primates, LD_{50} has been estimated 5–15 µg/kg depending on aerosol particle size. Inhalation of
275 particles that are able to penetrate deeply into the lungs (1-5 µm diameter) displays much more
276 toxicity than larger particles [72,80]. Inhalation of ricin causes slow onset of respiratory distress
277 (difficulty breathing), coughing, fever, pulmonary lesions and edema. Intoxicated animals develop
278 fibrinopurulent necrotizing pneumonia accompanied by necrotizing lymphadenitis, typically after a
279 dose-dependent delay of 8-24 hours. Death occurs for respiratory failure due to massive alveolar fluid

accumulation. Liver, kidney and small intestines appear congested although little histologic changes are shown [72,80,81].

Parenteral toxicity. Data regarding parenteral ricin intoxication derive mainly from animal lab. By injection, mice had an LD_{50} of 3-5 µg/kg by intravenous and 22 µg/kg by subcutaneous route [82], rabbits had LD_{50} 0.5 µg/kg by intravenous and 0.1 µg/kg by intramuscular route, while guinea pigs had LD_{50} <1.1 µg/kg by intravenous and 0.8 µg/kg by intramuscular route [83]. Human data derive from few cases of suicide or murder, or their attempt; the most known episode is the assassination of the Bulgarian dissident Georgi Markov who in 1978 died 3 days after being stabbed probably with an umbrella loaded with a ricin-containing pellet (Figure 1) [84].

By parenteral administration, immediate local pain at the injection site is reported, followed by general weakness within 5 hours. The following symptoms, that are general and maybe similar to sepsis (fever, headache, dizziness, anorexia, nausea, vomiting, hypotension, abdominal pain), can be delayed for as much as 10 to 12 hours, even with high doses. Usually local tissue damage at the site of the injection was observed. Laboratory abnormalities included elevated liver transaminases, amylase and creatinine kinase, hyperbilirubinemia, myoglobinuria and renal insufficiency. The clinical course may progress to multisystem organ failure. Preterminal complications included gastrointestinal hemorrhage, hypovolemic shock and renal failure [78,84].

4. Bioterrorism and environmental toxicity

Ricin is currently monitored as a Schedule 1A of the Chemical Weapons Convention (CWC) and is a Category B substance under the Biological and Toxins Weapons Convention (BTWC) [80]. Despite its toxicity, ricin is less potent than other agents such as botulinum neurotoxin or anthrax. It has been estimated that eight tons of ricin would have to be aerosolized over a 100 km^2 area to achieve about 50% casualty, whereas only kilogram quantities of anthrax spores would cause the same effect [85]. Thus, deploying an agent such as ricin over a wide area, although possible, becomes impractical from a logistics standpoint. However, the availability of castor beans and the quite simple procedure for rough ricin purification have attracted criminal and terrorist interest for small scale biocrimes or to cause collective media-driven alarm [80].

From castor seeds a nontoxic oil can be extracted that find a multitude of uses in many sectors, including cosmetic, pharmaceutic, mechanical and chemical industry. The castor oil production is increasing worldwide because of its versatile application, low cost, availability and biodegradability. In addition, the oil-free seed pulp can be used in agriculture as a natural fertilizer [86], although the processing of castor seeds requires great caution due to the high allergenicity [87,88] and extreme toxicity [76] of their protein fraction, represented above all by ricin. World production of castor oil increased from 0.8 million tons in 2000 [89] to 1.21 million tons in 2014 [90], with a castor seed production of 1.49 million tons in 2017 [91]. Leading producing countries are India, with over 80% of the global yield, Mozambique, China, Brazil, Myanmar, Ethiopia, Paraguay and Vietnam [92]. The oil makes up about 50% of the weight of the seeds and is mostly constituted of ricinoleic acid (90%), with minor amounts of dihydroxystearic, linoleic, oleic and stearic acids. Ricin isoforms and the alkaloid ricinine, are not transferred to the oil fraction during extraction, which can be performed by cold or warm pressing, but remain in the seed cake [93,94].

Castor bean meal press cake or other residues of the castor oil production have been employed as a protein source for feed or fertilizer, but their use is very limited by the ricin toxicity [76]. In 2008, the European Food Safety Agency defined ricin as undesirable substance in animal feed. Ricinus derived material should be appropriately inactivated through physical and/or chemical methods to guarantee animal and human health [95]. Nevertheless, many accidental poisonings are still reported for animals eating improperly detoxified fertilizer or other agricultural products containing castor derived material [76,94].

327   In order to block the toxic action of ricin, different strategies have been evaluated: vaccines,
328   inhibitors and passive immunity. Vaccines against ricin with the consequent production of
329   neutralizing antibodies did not give satisfactory results in vivo (reviewed in [96]). Inhibitors of ricin
330   can act blocking the active site or as substrate analogue; also in this case, the available data are limited
331   to in vivo experiments [97]. More recently, inhibitors of cell routing have been developed, sometimes
332   giving promising results also in vivo [98,99].

333   To date passive immunity has been proven the only effective strategy for treating intoxications
334   caused by ricin. The delay in the appearance of signs of intoxication makes confirmation of exposure,
335   diagnosis of intoxication and the subsequent medical response technically and logistically
336   challenging. The development of anti-ricin sera or antibodies, effective even when used several hours
337   after toxin exposure, represents a step forward in treatment of ricin intoxication, as it increases the
338   time window of intervention (WOO, window of opportunity). Many authors described effective post-
339   exposure treatment of ricin intoxication with specific antibodies, but with a limited WOO (~8 h) [100-
340   103]. Other authors reported a survival between 50 and 89% of mice treated with anti-sera 24 hours
341   after intoxication [104-106]. Once internalized into the cells, ricin cannot be neutralized by antibodies,
342   thus limiting the therapeutic window. However, Whitfield et al. in 2017 reported 100% protection in
343   aerosolized ricin-treated mice with a single administration of a F(ab')2 polyclonal ovine antitoxin
344   given 24 h post-exposure [107]. Even when performed in the same animal species, comparison
345   between diverse experiments is often difficult, due to the different toxin dose and route of
346   administration utilized. Moreover, there are few data about correlation between the antitoxin dose
347   required for protection and the WOO.

5. Ricin-containing immunotoxins

349   Many researchers tried to exploit the high ricin cytotoxicity for medical purposes to eliminate
350   pathological cells. Although ricin possesses highly efficient cell killing mechanisms, it lacks selectivity
351   towards cell targets. In order to increase selectivity, it has been explored the possibility of linking
352   ricin to carriers specific for targets on unwanted cells. The most widely used carriers are antibodies
353   and the corresponding conjugates are referred to as immunotoxins (ITs).
354   The first IT, created in 1976 by Moolten and co-workers, was made by Ricin Toxin-A chain (RTA)
355   linked to a rat tumor-specific antibody against a rat lymphoma, namely (C58NT)D (Figure 1) [108].
356   So far, a multitude of pre-clinical and clinical studies have shown the potential use of several ricin-
357   ITs towards different cancer types, from hematological to solid ones, and towards normal cells,
358   unwanted because responsible of a pathological state (reviewed in [109,110]). Different approaches
359   have been used, over time, to generate ITs. In the first strategy, ITs were composed by the antibody
360   chemically linked to the entire RIP that were used for in vitro and in vivo studies showing high
361   cytotoxicity [111]. Despite the high in vitro efficiency, the relevant non-specific toxicity reported in
362   vivo, due to the characteristics of the lectin chain, brought researchers to sterically block, chemically
363   modify or remove the B chain, thus balancing toxicity and specificity. In 1985, Weil-Hillman and
364   colleagues tested an anti-Mr 67,000 protein linked to either blocked-chain B ricin or RTA, in a nude
365   mouse model reporting interesting results in vitro but not in vivo [112]. The 80s were years of great
366   ferment for molecular biology and genetic engineering, paving the way for the second generation of
367   ITs. Many researchers tried to improve the IT penetration in tumor mass by reducing the antibody
368   size, using antigen-binding (Fab) or variable (Fv) fragments instead of entire antibodies. In 1988,
369   Ghetie and colleagues created a new IT composed by Fab' fragments conjugated to chemically
370   deglycosylated RTA (dgA) [113]. Few years later, they used an anti-CD122-dgA IT in SCID-Daudi
371   mice, showing promising results since the IT was able to specifically kill tumor cells in vivo,
372   extending the mean survival time up to 57.9 +/- 3.8 days [114]. Moreover, FitzGerald and co-workers
373   described the antitumor activity of recombinant RTA (rRTA) linked to anti-mouse transferrin
374   receptor in a nude mouse model of human ovarian cancer. Animals treated with IT extended life span

from 45 (lower doses) to 70/80 days (higher doses) [115]. Finally, in 1997 the first ricin-containing recombinant immunotoxin (rIT) was obtained through the expression of a fusion gene composed by sequences encoding anti-CD19-FVS191 (single-chain Fv), cathepsin D proteinase digestion site and rRTA. In this work, authors compared the cytotoxicity of the rIT with the chemical linked IT, evidencing that only the latter was toxic in target cells [116]. About 20 ricin-ITs have been tested in Phase I, II and III clinical trials to treat patients with either hematological or solid tumors, transplant rejection and GvHD. One of the first Phase I clinical trials has been conducted by Spitler and colleagues in 1987 (Figure 1), in which they obtained promising results by treating 22 metastatic malignant melanoma patients with an IT composed by murine monoclonal anti-melanoma antibody coupled to RTA (XOMAZYME-MEL) [117-119]. Additionally, ITs were also exploited for the treatment of autoimmune disease. Indeed, anti-CD5/RTA was the first IT to be used in clinical trials for therapy of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus and insulin-dependent diabetes mellitus [120,121].

A different approach can be represented by the construction of nanoparticles, in which ricin is genetically fused to carrier peptides that are able not only to recognize specific cellular target, but also to auto assemble, as stable nanoparticles, thus increasing the toxin-concentration into the targeted site [110,122,123].

6. Conclusions

In conclusion, ricin is a highly cytotoxic plant protein and has been of great utility to develop a number of anti-cancer immunotoxins. The ability of ricin, and of some other RIPs, to act on multiple molecular target inside the cell, thus triggering different death pathways, makes it more attractive for cancer treatment than conventional chemotherapy, in which one of the major problems is the rise of resistant cells [67,124]. However, ricin-containing ITs also exhibited many limitations like unspecific toxicity, organ toxicity (mainly liver, kidney and vasculature), immunogenicity, fast removal from blood stream, and lysosomal degradation inside cells. As a result, despite of the significant efforts made over the past few years, ricin as therapeutic agent has not been achieved much impact at the clinical level. The challenge is still open, and the frontline research is directed towards "recombinant immunotoxins" and nanocarriers, or, probably, by other novel techniques represented by expressing active plant toxin genes in vector specific for tumor cells [110,125].

Although ricin is not enough toxic to hypothesize a use over a wide area for terrorist purposes, the availability of castor beans and the quite simple procedure for rough ricin purification have stimulated the interest of criminals and terrorists for small-scale biocrimes. This justifies the researchers' efforts to obtain always more fast and sensitive ricin detection tests. In addition, the study of inhibiting or neutralizing molecules and the timing of clinical events in case of ricin intoxication could lead to the definition of one or more validated therapies.

Finally, the use of castor bean derivatives should be carefully monitored because of the potential presence of active ricin. In fact, the large use of these products in agriculture, without an effective ricin inactivation, caused several cases of animal intoxication and can be hazardous for human health.

Author Contributions: All the authors contribute to collect the literature, write and revise the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1.   D'Errico, F.; Backwell, L.; Villa, P.; Degano, I.; Lucejko, J.J.; Bamford, M.K.; Higham, T.F.; Colombini, M.P.; Beaumont, P.B. Early evidence of San material culture represented by organic artifacts from Border Cave, South Africa. *Proc. Natl. Acad. Sci. USA*, **2012**, *109*, 13214-13219.

421   2.   Ebers, G. *Papyros Ebers: Das Hermetische Buch über die Arzneimittel der Alten Äegypter*; Hinrichs, J.C., Ed.;
422   Wilhelm Engelmann: Leipzig, Germany, 1875.

423   3.   Leake, C.D. *The Old Egyptian Medical Papyri*; University of Kansas Press: Lawrence, KS, USA, 1952.

424   4.   Carpenter, S.; Rigaud, M.; Barile, M.; Priest, T.J.; Perez, L.; Ferguson, J.B. *An Interlinear Transliteration and
425   English Translation of Portions of the Ebers Papyrus Possibly Having to do with Diabetes Mellitus*; Bard College:
426   Annandale-on-Hudson, NY, USA, 1998.

427   5.   Totelin, L.M.V. *Hippocratic Recipes: Oral and Written Transmission of Pharmacological Knowledge in Fifth- and
428   Fourth-Century Greece*; Brill: Leiden, The Netherlands; Boston, MA, USA, 2009.

429   6.   Gunther, R.T. *The Greek herbal of Dioscorides/illustrated by a Byzantine, A.D. 512; Englished by John Goodyer,
430   A.D. 1655; edited and first printed, A.D. 1933*; Robert T. Gunther Ed., Oxford University Press, New York,
431   USA, 1934.

432   7.   Bostock, J.; Riley, H.T. *The Natural History of Pliny*, 1st ed.; Taylor and Francis, Red Lion Court, Fleet Street,
433   London, UK, 1855.

434   8.   Scarpa, A.; Guerci, A. Various uses of the castor oil plant (*Ricinus communis* L.). A review. *J. Ethnopharmacol*.
435   **1982**, *5*, 117-137.

436   9.   Ladda, P.L.; Kamthane R.B. *Ricinus communis* (castor): An overview. *Int. J. Res. Pharmacol. Pharmacother*.
437   **2014**, *3*, 136-144.

438   10.   Quattrocchi, U. CRC *World dictionary of medicinal and poisonous plants: common names, scientific names,
439   eponyms, synonyms, and etymology*; Routledge: Abingdon-on-Thames, UK, 2012.

440   11.   Polito, L.; Bortolotti, M.; Maiello, S.; Battelli, M.G.; Bolognesi, A. Plants producing Ribosome-Inactivating
441   Proteins in traditional medicine. *Molecules* **2016**, *21*, E1560.

442   12.   Tunaru, S.; Althoff, T.F.; Nüsing, R.M.; Diener, M.; Offermanns, S. Castor oil induces laxation and uterus
443   contraction via ricinoleic acid activating prostaglandin EP3 receptors. *Proc. Natl. Acad, Sci. U.S.A.* **2012**, *109*,
444   9179-9184.

445   13.   Adeniyi, O.S.; Omale, J.; Omeje, S.C.; Edino, V.O. Antidiarrheal activity of hexane extract of Citrus limon
446   peel in an experimental animal model. *J. Integr. Med*. **2017**, *15*, 158-164.

447   14.   Battelli, M.G. Cytotoxicity and toxicity to animals and humans of ribosome-inactivating proteins. *Mini Rev.
448   Med. Chem*. **2004**, *4*, 513-521.

449   15.   Barbieri, L.; Battelli, M.G.; Stirpe, F. Ribosome-inactivating proteins from plants. *Biochim. Biophys. Acta* **1993**,
450   *1154*, 237-282.

451   16.   Dixson, T. *Ricinus communis*. *Aust. Med. Gazz*. **1887**, *6*, 137-138.

452   17.   Hartmut, F. The ricin story. In: *Advances In Lectin Research, Volume 1,* Hartmut Franz Ed.; Springer-Verlag:
453   Heidelberg, Germany, 1988; pp. 10-25.

454   18.   Stillmark, H. Über Ricin, ein giftiges Ferment aus den Samen von Ricinus communis L. und einigen
455   anderen Euphorbiaceen. M.D. Dissertation Thesis, University of Dorpat, Dorpat, Estonia, 1888.

456   19.   Takahashi, T.; Funatsu, G.; Funatsu, M. Biochemical studies on castor bean hemagglutinin. I. Separation
457   and purification. *J. Biochem*. **1962**, *51*, 288-292.

458   20.   Ehrlich, P. Experimentelle Untersuchungen über Immunität I. Über Ricin. *Dtsch. Med. Wochenschr*. **1891**, *17*,
459   976-979.

460   21.   Ehrlich, P. Experimentelle Untersuchungen über Immunität II. Über Abrin. *Dtsch. Med. Wochenschr*. **1891**,
461   *17*, 1218-1219.

462   22.   Silverstein, A.M. Paul Ehrlich: the founding of pediatric immunology. *Cell Immunol*. **1996**, *174*, 1-6.

463 23. Ehrlich, P. Partial Cell Functions. In: *Nobel Lectures, Physiology or Medicine 1901-1921*; Elsevier Publishing
464   Company: Amsterdam, Netherlands, 1967.
465 24. Lin, J.Y.; Tserng, K.Y.; Chen, C.C.; Lin, L.T.; Tung, T.C. Abrin & Ricin: New anti-tumour substances. *Nature*
466   **1970**, *227*, 292-293.
467 25. Lin, J.Y.; Liu, K.; Chen, C.C.; Tung, T.C. Effect of crystalline ricin on the biosynthesis of protein, RNA, and
468   DNA in experimental tumor cells. *Cancer Res*. **1971**, *31*, 921-924.
469 26. Olsnes, S.; Pihl, A. Different biological properties of the two constituent peptide chains of ricin, a toxic
470   protein inhibiting protein synthesis. *Biochemistry* **1973**, *12*, 3121-3126.
471 27. Olsnes, S.; Pihl A. Inhibition of peptide chain elongation. *Nature* **1972**, *238*, 459-461.
472 28. Funatsu, G.; Yoshitake, S.; Funatsu, M. Primary Structure of Ile Chain of Ricin D. *Agric. Biol. Chem*. **1978**,
473   *42*, 501-503.
474 29. Funatsu, G.; Kimura, M.; Funatsu, M. Primary Structure of Ala Chain of Ricin D. *Agric. Biol. Chem*. **1979**, *43*,
475   2221-2224.
476 30. Montfort, W.; Villafranca, J.E.; Monzingo, A.F.; Ernst, S.R.; Katzin, B.; Rutenber, E.; Xuong, N.H.; Hamlin,
477   R.; Robertus, J.D. The three-dimensional structure of ricin at 2.8 A. *J. Biol. Chem*. **1987**, *262*, 5398-5403.
478 31. Rutenber, E.; Katzin, B.J.; Ernst, S.; Collins, E.J.; Mlsna, D.; Ready, M.P.; Robertus, J.D. Crystallographic
479   refinement of ricin to 2.5 A. *Proteins* **1991**, *10*, 240-250.
480 32. Katzin, B.J.; Collins, E.J.; Robertus, J.D. Structure of ricin A-chain at 2.5 A. *Proteins* **1991**, *10*, 251-259.
481 33. Rutenber, E.; Robertus, J.D. Structure of ricin B-chain at 2.5 A resolution. *Proteins* **1991**;*10*, 260-269.
482 34. Weston, S.A.; Tucker, A.D.; Thatcher, D.R.; Derbyshire, D.J.; Pauptit, R.A. X-ray structure of recombinant
483   ricin A-chain at 1.8 A resolution. *J. Mol. Biol*. **1994**, *244*, 410-422.
484 35. Vater, C.A.; Bartle, L.M.; Leszyk, J.D.; Lambert, J.M.; Goldmacher, V.S. Ricin A chain can be chemically
485   cross-linked to the mammalian ribosomal proteins L9 and L10e. *J. Biol. Chem*. **1995**, *270*, 12933–12940.
486 36. Monzingo, A.F.; Robertus, J.D. X-ray analysis of substrate analogs in the ricin A-chain active site. *J. Mol.
487   Biol*. **1992**, *227*, 1136-1145.
488 37. Ready, M.P.; Kim, Y.; Robertus, J.D. Site-directed mutagenesis of ricin A-chain and implications for the
489   mechanism of action. Proteins 1991, 10, 270-278.
490 38. Olsnes, S.; Pihl, A. Ricin - a potent inhibitor of protein synthesis. *FEBS Lett*. **1972**, *20*, 327-329.
491 39. Sperti, S.; Montanaro, L.; Mattioli, A.; Stirpe, F. Inhibition by ricin of protein synthesis in vitro: 60 S
492   ribosomal subunit as the target of the toxin. *Biochem. J*. **1973**, *136*, 813-815.
493 40. Montanaro, L.; Sperti, S.; Stirpe, F. Inhibition by ricin of protein synthesis in vitro. Ribosomes as the target
494   of the toxin. *Biochem. J*. **1973**, *136*, 677-683.
495 41. Sperti, S.; Montanaro, L.; Mattioli, A.; Testoni, G. Relationship between elongation factor I- and elongation
496   factor II- dependent guanosine triphosphatase activities of ribosomes. Inhibition of both activities by ricin.
497   *Biochem. J*. **1975**, *148*, 447-451.
498 42. Benson, S.; Olsnes, S.; Pihl, A.; Skorve, J.; Abraham, A.K. On the mechanism of protein-synthesis inhibition
499   by abrin and ricin. Inhibition of the GTP-hydrolysis site on the 60-S ribosomal subunit. *Eur. J. Biochem*. **1975**,
500   *59*, 573-580.
501 43. Olsnes, S.; Fernandez-Puentes, C.; Carrasco, L.; Vazquez, D. Ribosome inactivation by the toxic lectins abrin
502   and ricin. Kinetics of the enzymic activity of the toxin A-chains. *Eur. J. Biochem*. **1975**, *60*, 281–288.
503 44. Barbieri, L.; Stirpe, F. Ribosome-inactivating proteins from plants: properties and possible uses. *Cancer Surv*.
504   **1982**, *1*, 489-52.

505   45.   Bolognesi, A.; Bortolotti, M.; Maiello, S.; Battelli, M.G.; Polito, L. Ribosome-Inactivating Proteins from
506   Plants: A Historical Overview. *Molecules* **2016**, *21*, E1627.

507   46.   Endo, Y.; Tsurugi, K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin
508   ricin on eukaryotic ribosomes. *J. Biol. Chem.* **1987**, *262*, 8128-8130.

509   47.   Endo, Y.; Mitsui, K.; Motizuki, M.; Tsurugi, K. The mechanism of action of ricin and related toxic lectins on
510   eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by
511   the toxins. *J. Biol. Chem.* **1987**, *262*, 5908-5912.

512   48.   Barbieri, L.; Valbonesi, P.; Bonora, E.; Gorini, P.; Bolognesi, A.; Stirpe, F. Polynucleotide:adenosine
513   glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A). *Nucleic Acids Res.*
514   **1997**, *25*, 518-522.

515   49.   Barbieri, L.; Bolognesi, A.; Valbonesi, P.; Polito, L.; Olivieri, F.; Stirpe, F. Polynucleotide: adenosine
516   glycosidase activity of immunotoxins containing ribosome-inactivating proteins. *J. Drug Target.* **2000**, *8*, 281-
517   288.

518   50.   Barbieri, L.; Brigotti, M.; Perocco, P.; Carnicelli, D.; Ciani, M.; Mercatali, L.; Stirpe, F. Ribosome-inactivating
519   proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity
520   for 3T3 fibroblasts. *FEBS Lett.* **2003**, *538*, 178-182.

521   51.   Brigotti, M.; Alfieri, R.; Sestili, P.; Bonelli, M.; Petronini, P.G.; Guidarelli, A.; Barbieri, L.; Stirpe, F.; Sperti,S.
522   Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. *FASEB J.* **2002**, *16*,
523   365-372.

524   52.   Sandvig, K.; Olsnes, S.; Pihl, A. Kinetics of binding of the toxic lectins abrin and ricin to surface receptors
525   of human cells. *J. Biol. Chem.* **1976**, *251*, 3977-3984.

526   53.   van Deurs, B.; Petersen, O.W.; Sundan, A.; Olsnes, S.; Sandvig, K. Receptor-mediated endocytosis of a ricin-
527   colloidal gold conjugate in Vero cells: intracellular routing to vacuolar and tubulo-vesicular portions of the
528   endosomal system. *Exp. Cell Res.* **1985**, *159*, 287-304.

529   54.   Moya, M.; Dautry-Varsat, A.; Goud, B.; Louvard, D.; Boquet, P. Inhibition of coated pit formation in Hep2
530   cells blocks the cytotoxicity of diphtheria toxin but not that of ricin. *J. Cell Biol.* **1985**, *101*, 548-559.

531   55.   van Deurs, B.; Sandvig, K., Petersen, O.W.; Olsnes, S.; Simons, K.; Griffiths, G. Routing of internalised ricin
532   and ricin conjugates to the Golgi complex. *J. Cell Biol.* **1986**, *102*, 37-47.

533   56.   Sandvig, K.; van Deurs, B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin.
534   *Physiol. Rev.* **1996**, *76*, 949-966.

535   57.   Cosson, P.; Letourneur, F. Coatamer interaction with di-lysine endoplasmic reticulum retention motifs,
536   *Science* **1994**, *263*, 1629-1631.

537   58.   Chen, A.; Hu, T.; Mikoryak, C.; Draper, R.K. Retrograde transport of protein toxins under conditions of
538   COPI dysfunction. *Biochim. Biophys. Acta* **2002**, *1589*, 124-139.

539   59.   Wesche, J.; Rapak, A.; Olsnes, S. Dependence of ricin toxicity on translocation of the toxin A-chain from the
540   endoplasmic reticulum to the cytosol. *J. Biol. Chem.* **1999**, *274*, 34443-34449.

541   60.   Sandvig, K.; Bergan, J.; Kavaliauskiene, S.; Skotland, T. Lipid requirements for entry of protein toxins into
542   cells. *Prog. Lipid Res.* **2014**, *54*, 1-13.

543   61.   Roberts, L.M.; Smith, D.C. Ricin: the endoplasmic reticulum connection. *Toxicon* **2004**, *44*, 469-472.

544   62.   Eiklid, K.; Olsnes, S.; Pihl, A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa
545   cells. *Exp. Cell. Res.* **1980**, *126*, 321-326.

546   63.   Harper, C.G.; Gonatas, J.O.; Mizutani, T.; Gonatas, N.K. Retrograde transport and effects of toxic ricin in

547   the autonomic nervous system. *Lab. Invest*. **1980**, *42*, 396-404.

548   64.   Polito, L.; Bortolotti, M.; Farini, V.; Battelli, M.G.; Barbieri, L.; Bolognesi, A. Saporin induces multiple death
549   pathways in lymphoma cells with different intensity and timing as compared to ricin. *Int. J. Biochem. Cell*
550   *Biol*. **2009**, *41*, 1055–1061.

551   65.   Tazzari, P.L.; Bolognesi, A.; de Totero, D.; Falini, B.; Lemoli, R.M.; Soria, M.R.; Pileri, S.; Gobbi, M.; Stein,
552   H.; Flenghi, L.; Martelli, M.F.; Stirpe, F. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the
553   treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. *Br. J. Haematol*. **1992**, 81, 203-
554   211.

555   66.   Ngo, T.N.; Nguyen, T.T.; Bui D.T-T.; Hoang N.T-M.; Nguyen, T.D. Effects of ricin extracted from seeds of
556   the castor bean (ricinus communis) on cytotoxicity and tumorigenesis of melanoma cells. *Biomed. Res. Ther*.
557   **2016**, *3*, 633-644.

558   67.   Polito, L.; Bortolotti, M.; Pedrazzi, M.; Mercatelli, D.; Battelli, M.G.; Bolognesi, A. Apoptosis and necroptosis
559   induced by stenodactylin in neuroblastoma cells can be completely prevented through caspase inhibition
560   plus catalase or necrostatin-1. *Phytomedicine* **2016**, *23*, 32-41.

561   68.   Roxas-Duncan, V.I.; Smith L.A. Of Beans and Beads: Ricin and abrin in bioterrorism and biocrime. *J. Bioterr.*
562   *Biodef*. **2012**, *S2*, 002.

563   69.   Whitfield, S.J.C.; Griffiths, G.D.; Jenner, D.C.; Gwyther, R.J.; Stahl, F.M.; Cork, L.J.; Holley, J.L.; Green, A.C.;
564   Clark, G.C. Production, characterisation and testing of an ovine antitoxin against ricin; efficacy, potency
565   and mechanisms of action. *Toxins (Basel)* **2017**, *9*, E329.

566   70.   Audi, J.; Belson, M.; Patel, M.; Schier, J.; Osterloh, J. Ricin poisoning – a comprehensive review. *JAMA* **2005**,
567   *294*, 2342-2351.

568   71.   Cook, D.L.; David, J.; Griffiths, G.D. Retrospective identification of ricin in animal tissues following
569   administration by pulmonary and oral routes. *Toxicology* **2006**, *223*, 61-70.

570   72.   Roy, C.J.; Song, K.; Sivasubramani, S.K.; Gardner, D.J.; Pincus, S.H. Animal models of ricin toxicosis. *Curr.*
571   *Top. Microbiol. Immunol*. **2012**, *357*, 243-257.

572   73.   He, X.; Carter, J.M.; Brandon, D.L.; Cheng, L.W.; McKeon, T.A. Application of a real time polymerase chain
573   reaction method to detect castor toxin contamination in fluid milk and eggs. *J. Agric.Food Chem*. **2007**, *55*,
574   6897-6902.

575   74.   Olsnes, S. The history of ricin, abrin and related toxins. *Toxicon* **2004**, *44*, 361-370.

576   75.   Wedin, G.P.; Neal, J.S.; Everson, G.W.; Krenzelok, E.P. Castor bean poisoning. *Am. J. Emerg. Med*. **1986**, *4*,
577   259-261.

578   76.   Worbs, S.; Köhler, K.; Pauly, D.; Avondet, M.A.; Schaer, M.; Dorner, M.B.; Dorner, B.G. *Ricinus communis*
579   intoxications in human and veterinary medicine-a summary of real cases. *Toxins (Basel)* **2011**, *3*, 1332-1372.

580   77.   Grimshaw, B.; Wennike, N.; Dayer, M. Ricin poisoning: a case of internet-assisted parasuicide. *Br. J. Hosp.*
581   *Med. (Lond)* **2013**, *74*, 532-533.

582   78.   Bradberry, S. Ricin and abrin. *Medicine* **2016**, *44*, 109–110.

583   79.   Bradberry, S.M.; Dickers, K.J.; Rice, P.; Griffiths, G.D.; Vale, J.A. Ricin poisoning. *Toxicol. Rev*. **2003**, *22*, 65-
584   70.

585   80.   OPCW - Organisation for the Prohibition of Chemical Weapons. Ricin Fact Sheet (2014). Available online:
586   https://www.opcw.org/sites/default/files/documents/SAB/en/sab-21-wp05_e_.pdf (accessed on 15 April
587   2019).

588   81.   Pincus, S.H.; Bhaskaran, M.; Brey, R.N.3rd; Didier, P.J.; Doyle-Meyers, L.A.; Roy. C.J. Clinical and
589   Pathological Findings Associated with Aerosol Exposure of Macaques to Ricin Toxin. *Toxins (Basel)* **2015**, *7*,
590   2121-2133.

591   82.   Franz, D.R.; Jaax, N.K. Ricin Toxin. In*: Medical Aspects of Chemical and Biological Warfare*; Sidell F.R., Takafuji,
592   E.T. & Franz, D.R., Eds.; Walter Reed Army Medical Center, Borden Institute, Washington DC, USA, 1997;
593   Volume 3, pp. 631-642

594   83.   Millard, C.; LeClaire, R. Ricin and related toxins: review and perspective. In: *Chemical Warfare Agents:*
595   *Chemistry, Pharmacology, Toxicology, and Therapeutics*, 2nd ed.; Brian J. Lukey, James A. Romano Jr., James A.
596   Romano, Harry Salem, Brian J Lukey, Harry Salem Eds.; CRC Press, Taylor & Francis Group, Boca Raton
597   FL, USA, 2007; pp. 424-452.

598   84.   Crompton, R.; Gall, D. Georgi Markov- death in a pellet. *Med. Leg. J.* **1980**, *48*, 51-62.

599   85.   Kortepeter, M.G.; Parker, G.W. Potential biological weapons threats. *Emerg. Infect. Dis*. **1999**, *5*, 523-527.

600   86.   Mubofu, E.B. Castor oil as a potential renewable resource for the production of functional materials. *Sustain*
601   *Chem. Process* **2016**, *4*, 11.

602   87.   Ordman, D. An outbreak of bronchial asthma in South Africa, affecting more than 200 persons, caused by
603   castor bean dust from an oil processing factory. *Int. Arch. Allergy Appl. Immunol*. **1955**, *7*, 10-24.

604   88.   Panzani, R.C. Respiratory castor bean dust allergy in the south of France with special reference to
605   Marseilles. *Int. Arch. Allergy Appl. Immunol*. **1957**, *11*, 224-236.

606   89.   Weiss, E.A. 2000. Castor. In *Oilseed Crops*, 2nd ed.; Blackwell Science Ltd., Oxford, UK, 2000, pp. 31-36.

607   90.   Vashst, D.; Amhad, M. Statistical analysis of diesel engine performance for castor and jatropha biodiesel-
608   blended fuel. *IJAME* **2014**, *10*, 2155-2169.

609   91.   Falk, S. World Outlook for Castor Oil 2018. Proceedings of the Global Castor Conference 2018, Ahmedabad,
610   India, 23-24 Feb 2018.

611   92.   Food and Agriculture Organization of United States (FAO), 2017. Available online: (accessed on 15 April
612   2019).

613   93.   Patel, V.R.; Dumancas, G.G.; Kasi Viswanath, L.C.; Maples, R.; Subong, B.J. Castor oil: properties, uses, and
614   optimization of processing parameters in commercial production. *Lipid Insights*, **2016**, *9*, 1-12.

615   94.   Alexander, J.; Benford, D.; Cockburn, A.; Cravedi, J-P.; Dogliotti, E.; Di Domenico, A.; Férnandez-Cruz,
616   M.L.; Fürst, P.; Fink-Gremmels, J.; Galli, C.L.; Grandjean, P.; Gzyl, J.; Heinemeyer, G.; Johansson, N.; Mutti,
617   A.; Schlatter, J.; van Leeuwen, R.; van Peteghem, C.; Verger, P. Scientific Opinion of the Panel on
618   Contaminants in the Food Chain on a request from the European Commission on ricin (from *Ricinus*
619   *communis*) as undesirable substances in animal feed. *EFSA Journal* **2008**, *726*, 9-38. doi:
620   10.2903/j.efsa.2008.726.

621   95.   Anandan, S.; Kumar, G.; Ghosh, J.; Ramachandra, K. Effect of different physical and chemical treatments
622   on detoxification of ricin in castor cake. *Anim. Feed Sci. Tech*. **2004**, *120*, 159-168.

623   96.   Smallshaw, J.E.; Vitetta, E.S. Ricin vaccine development. *Curr. Top. Microbiol. Immunol*. **2012**, *357*, 259-272.

624   97.   Rainey, G.J.; Young, J.A. Antitoxins: novel strategies to target agents of bioterrorism. *Nat. Rev. Microbiol*.
625   **2004**, *2*, 721-726.

626   98.   Stechmann, B.; Bai, S.K.; Gobbo, E.; Lopez, R.; Merer, G.; Pinchard, S.; Panigai, L.; Tenza, D.; Raposo, G.;
627   Beaumelle, B.; Sauvaire, D.; Gillet, D.; Johannes, L.; Barbier, J. Inhibition of retrograde transport protects
628   mice from lethal ricin challenge. *Cell* **2010**, *141*, 231-242.

629   99.   Barbier, J.; Bouclier, C.; Johannes, L.; Gillet, D. Inhibitors of the cellular trafficking of ricin. *Toxins (Basel)*
630   **2012**, *4*, 15-27.

631   100. Gal, Y.; Mazor, O.; Alcalay, R.; Seliger, N.; Aftalion, M.; Sapoznikov, A.; Falach, R.; Kronman, C.; Sabo, T.
632   Antibody/doxycycline combined therapy for pulmonary ricinosis: Attenuation of inflammation improves

633   survival of ricin-intoxicated mice. *Toxicol. Rep*. **2014**, *1*, 496–504.

634   101. O'Hara, J.M.; Whaley, K.; Pauly, M.; Zeitlin, L.C.; Mantis, N. Plant-based expression of a partially
635   humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin
636   A subunit. *Vaccine* **2012**, *30*, 1239–1243.

637   102. Sully, E.K.; Whaley, K.J.; Bohorova, N.; Goodman, C.; Kim, D.H.; Pauly, M.H.; Velasco, J.; Hiatt, E.; Morton,
638   J.; Swope, K.; Roy, C.J.; Zeitlin, L.; Mantis, N.J. Chimeric plantibody passively protects mice against
639   aerosolized ricin challenge. *Clin. Vaccine Immunol*. **2014**, *21*, 777–782.

640   103. Van Slyke, G.; Sully, E.K.; Bohorova, N.; Bohorov, O.; Kim, D.; Pauly, M.; Whaley, K.; Zeitlin, L.; Mantis, N.J.
641   Humanized monoclonal antibody that passively protects mice 3 against systemic and intranasal ricin toxin
642   challenge. *Clin. Vaccine Immunol*. **2016**, *23*, 795-799.

643   104. Pratt, T.S.; Pincus, S.H.; Hale, M.L.; Moreira, A.L.; Roy, C.J.; Tchou-Wong, K.-M. Oropharyngeal aspiration
644   of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A chain
645   for post-exposure treatment. *Exp. Lung Res*. **2007**, *33*, 459–481.

646   105. Noy-Porat, T.; Alcalay, R.; Epstein, E.; Sabo, T.; Kronman, C. Extended therapeutic window for post
647   exposure treatment of ricin intoxication conferred by the use of high-affinity antibodies. *Toxicon* **2017**, *127*,
648   100–105.

649   106. Noy-Porat, T.; Rosenfeld, R.; Ariel, N.; Epstein, E.; Alcalay, R.; Zvi, A.; Kronman, C.; Ordentlich, A.; Mazor,
650   O. Isolation of anti-ricin protective antibodies exhibiting high affinity from immunized non-human
651   primates. *Toxins (Basel)* **2016**, *8*, E64.

652   107. Whitfield, S.J.C.; Griffiths, G.D.; Jenner, D.C.; Gwyther, R.J.; Stahl, F.M.; Cork, L.J.; Holley, J.L.; Green, A.C.;
653   Clark, G.C. Production, characterisation and testing of an ovine antitoxin against ricin; efficacy, potency
654   and mechanisms of action. *Toxins (Basel)*. **2017**, *9*, E329.

655   108. Moolten, F.; Zajdel, S.; Cooperband, S. Immunotherapy of experimental animal tumors with antitumor
656   antibodies conjugated to diphtheria toxin or ricin. *Ann. N. Y. Acad. Sci*. **1976**, *277*, 690-699.

657   109. Gilabert-Oriol, R.; Weng, A.; Mallinckrodtm Bv.; Melzig, M.F.; Fuchs, H.; Thakur, M. Immunotoxins
658   constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific
659   efficacy. *Curr. Pharm. Des*. **2014**, *20*, 6584-6643.

660   110. Tyagi, N.; Tyagi, M.; Pachauri, M.; Ghosh, P.C. Potential therapeutic applications of plant toxin-ricin in
661   cancer: challenges and advances. *Tumour Biol*. **2015**, *36*, 8239-8246.

662   111. Blythman, H.E.; Casellas, P.; Gros, O.; Gros, P.; Jansen, F.K.; Paolucci, F.; Pau, B.; Vidal, H. Immunotoxins:
663   hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells. *Nature* **1981**,
664   *290*, 145-146.

665   112. Weil-Hillman, G.; Runge, W.; Jansen, F.K.; Vallera, D.A. Cytotoxic effect of anti-Mr 67,000 protein
666   immunotoxins on human tumors in a nude mouse model. *Cancer Res*. **1985**, *45*, 1328-1336.

667   113. Ghetie, V.; Ghetie, M.A.; Uhr, J.W.; Vitetta, E.S. Large scale preparation of immunotoxins constructed with
668   the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain. *J.
669   Immunol. Methods* **1988**, *112*, 267-277.

670   114. Ghetie, M.A.; Richardson, J.; Tucker, T.; Jones, D.; Uhr, J.W.; Vitetta, E.S. Antitumor activity of Fab' and IgG-
671   anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined
672   immunodeficiency disease: effect on tumor cells in extranodal sites. *Cancer Res*. **1991**, *51*, 5876-5880.

673   115. FitzGerald, D.J.; Bjorn, M.J.; Ferris, R.J.; Winkelhake, J.L.; Frankel, A.E.; Hamilton, T.C.; Ozols, R.F.;
674   Willingham, M.C.; Pastan, I. Antitumor activity of an immunotoxin in a nude mouse model of human

675   ovarian cancer. *Cancer Res*. **1987**, *47*, 1407-1410.

676 116. Wang, D.; Li, Q.; Hudson, W.; Berven, E.; Uckun, F.; Kersey, J.H. Generation and characterization of an anti-
677   CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA. *Bioconjug. Chem*.
678   **1997**, *8*, 878-884.

679 117. Hertler, A.A.; Splitler, L.; Frankel, A. Humoral immune response to a ricin A chain immunotoxin in patients
680   with metastatic melanoma. *Cancer Drug Deliv*. **1987**, *4*, 245-253.

681 118. Spitler, L.E.; del Rio, M.; Khentigan, A.; Wedel, N.I.; Brophy, N.A.; Miller, L.L.; Harkonen, W.S.; Rosendorf,
682   L.L.; Lee, H.M.; Mischak, R.P.; Kawahata, R.T.; Stoudemire, J.B.; Fradkin, L.B.; Bautista, E.E.; Scannon, P.J.
683   Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain
684   immunotoxin. *Cancer Res*. **1987**, *47*, 1717-1723.

685 119. Mischak, R.P.; Foxall, C.; Rosendorf, L.L.; Knebel, K.; Scannon, P.J.; Spitler, L.E. Human antibody responses
686   to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin Xoma-Zyme-MEL.
687   *Mol. Biother*. **1990**, *2*, 104-109.

688 120. Strand, V.; Lipsky, P.E.; Cannon, G.W.; Calabrese, L.H.; Wiesenhutter, C.; Cohen, S.B.; Olsen, N.J.; Lee,
689   M.L.;Lorenz, T.J.; Nelson, B. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid
690   arthritis. Results of two phase II studies. The CD5 plus rheumatoid arthritis investigators group. *Arthritis
691   Rheum*. **1993**, *36*, 620-630.

692 121. Stafford, F.J.; Fleisher, T.A.; Lee, G.; Brown, M.; Strand, V.; Austin, H.A.; Balow, J.E.; Klippel, J.H. A pilot
693   study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus. *J. Rheumatol*. **1994**, *21*,
694   2068-2070.

695 122. Ashley, C.E.; Carnes, E.C.; Phillips, G.K.; Durfee, P.N.; Buley, M.D.; Lino, C.A.; Padilla, D.P.; Phillips, B.;
696   Carter, M.B.; Willman, C.L.; Brinker, C.J.; Caldeira, C.; Chackerian, B., Wharton, W.; Peabody, D.S. Cell-
697   specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. *ACS Nano* **2011**, 5, 5729-5745.

698 123. Díaz, R.; Pallarès, V.; Cano-Garrido, O.; Serna, N.; Sánchez-García, L.; Falgàs, A.; Pesarrodona, M.; Unzueta,
699   U.; Sánchez-Chardi, A.; Sánchez, J.M.; Casanova, I.; Vázquez, E.; Mangues, R.; Villaverde, A. Selective
700   CXCR4(+) cancer cell targeting and potent antineoplastic effect by a nanostructured version of recombinant
701   ricin. *Small* **2018**, *14*, e1800665.

702 124. Polito, L.; Mercatelli, D.; Bortolotti, M.; Maiello, S.; Djemil, A.; Battelli, M.G.; Bolognesi, A. Two Saporin-
703   Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma
704   Cells. *Toxins (Basel)* **2017**, *9*, E182.

705 125. Zhang, Y.H.; Wang, Y.; Yusufali, A.H.; Ashby, F.; Zhang, D.; Yin, Z.F.; Aslanidi, G.V.; Srivastava, A.; Ling,
706   C.Q.; Ling, C. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and
707   in vivo. *J. Integr. Med*. **2014**, *12*, 483-494.

708

709